Long COVIDNCT05699538
Fatigability in Long COVID-19
A study testing Minimal-Dose Home-Based Resistance Exercise in people with Long COVID, run by VA Office of Research and Development at 1 site in United States.
Trial summary
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Long COVID
- What is being tested?
- Minimal-Dose Home-Based Resistance Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jul 2023to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ambulatory patients (with or without a gait aid)
- 50 years of age or older
- with a confirmed diagnosis of COVID-19 by polymerase chain reaction (PCR) test, antibody test or clinical diagnosis
- the symptom of fatigue reported greater than 12-weeks post-infection (reporting fatigue: yes/no)
- receiving care at the DC VAMC
- the ability to speak and read English, and orientation to person, place, and time
Show all 12Show fewer
- the comparison group will include ambulatory patients (with or without a gait aid)
- 50 years of age or older
- with a confirmed diagnosis of COVID-19 by PCR test, antibody test or clinical diagnosis
- without the symptom of fatigue reported greater than 12-weeks post-infection
- receiving care at the DC VAMC
- the ability to speak and read English, and orientation to person, place, and time
Who cannot join
- <50 years of age without a confirmed diagnosis of COVID-19 by PCR test
- antibody test or clinical diagnosis or with a confirmed diagnosis of COVID-19 of <12-weeks
- non-ambulatory individuals
- Veterans who do not use the DC VAMC as their main site for care
- body mass index 40 kg/m2
- diagnosis of psychiatric disorder(s)
Show all 10Show fewer
- any medically uncontrolled cardiovascular
- musculoskeletal disease, or other conditions that, in the opinion of the principal investigator, could make participation in the study unsafe
- any orthopedic or joint pain which would prevent the participant from safely engaging in the study protocol
- additionally, individuals with plans to relocate from the DC metro area within one year will not be eligible for the intervention portion of the study
Trial locations and contacts
1 site in 1 country.
United States1 site
Washington DC VA Medical Center, Washington, DC
Washington D.C., District of Columbia, 20422-0001
About this study
Official title: Fatigue and Fatigability in Veterans Following SARS-CoV-2 Infection
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. The central hypothesis is that declines in force capacity, skeletal muscle oxygen extraction, and affective responses to physical activity offer potential mechanisms through which fatigability is increased in Veterans with post-COVID-19 fatigue. Moreover, home-based resistance exercise delivered remotely may provide a safe and feasibility treatment option for targeting neuromuscular and neurobehavioral factors influencing fatigability severity in this population.
Read the detailed description
The clinical case definition of post-COVID-19 condition (also referred to as Long COVID) as defined by the World Health Organization (WHO) includes individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Fatigue represents one of the most frequently reported symptoms in individuals experiencing post-COVID-19 (i.e., post-COVID-19 fatigue; PCF).Fatigue is shown to persist for months after SARS-CoV-2 infection, negatively impacting activities of daily living. For the purposes of this SPiRE proposal, fatigue is operationally defined as a state characteristic encompassing a subjective lack of physical and/or mental energy that is perceived by the individual to interfere with usual or desired activities.
Increased fatigability is a possible complication following SARS-CoV-2 infection due to the presence of both neuromuscular and neurobiological consequences. Skeletal muscle alterations including reduced force capacity, fiber atrophy, mitochondria and metabolic dysfunction, and capillary impairments have been observed in patients following SARS-CoV-2 infection. Autopsy reports of patients who died after SARS-CoV-2 infection found evidence of skeletal muscle atrophy of type 2 fibers, necrotizing myopathy, and myositis. Similarly, using nerve conduction studies, patients with long-term COVID-19 were found to have signs of myopathy, even those who were not hospitalized. Evidence from cardiopulmonary exercise testing in patients diagnosed with COVID-19 has revealed impaired skeletal muscle oxygen extraction, as opposed to central limitations (i.e., cardiac output), as a determinant of exercise intolerance. In addition to neuromuscular complications, SARS-CoV-2 infection has also been shown to be associated with psychiatric sequelae. Collectively, these findings underscore neuromuscular as well as neurobiological consequences of SARS-CoV-2 as potential independent or co-occurring mechanisms by which increased fatigability occurs and persists.
Despite widespread calls for the importance of rehabilitation in individuals recovering from SARS-CoV-2 infection, little progress has been made regarding the potential benefits of physical exercise on fatigue and fatigability in this population. Moreover, concerns have been raised about the applicability of physical exercise in patients recovering from SARS-CoV-2 infection. For example, while the health and functional benefits of exercise are vast and widely known, in certain patient populations exertion is shown to exacerbate symptom severity. Some individuals with PCF may report experiencing worsening of symptoms after physical or mental exertion. Home-based exercise may offer an appealing option for those individuals concerned about attending community fitness facilities. Home-based exercise is shown to produced moderate effects on muscle strength and balance. Presently, the exact dosing of home-based exercise to elicit positive outcomes in fatigability is unknown. Minimal-dose resistance exercise has been proposed as a potential strategy for improving neuromuscular characteristics and physical function. Minimal-dose resistance exercise uses little to no equipment with exercises performed at lower workloads. The investigators aim to adapt the "minimal-dose" resistance exercise paradigm to a remote home-based resistance exercise program for Veterans with PCF to determine its implications for reducing fatigability and improving neuromuscular and neurobiological factors. Minimal-dose resistance exercise for the proposed application is defined as a single, weekly body-weight exercise session.
- Conditions
- Long COVID
- Being tested
- Minimal-Dose Home-Based Resistance Exercise
- Keywords
- resistance exercise, fatigue, COVID-19, near infrared spectroscopy, strength
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Fatigue, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Minimal-Dose Home-Based Resistance ExerciseBehavioural
8-week home-based resistance exercise performed one day per week.
| Study group | Role | What they receive |
|---|---|---|
| Minimal-Dose Home-Based Resistance Exercise | Experimental | 8-week home-based resistance exercise performed one day per week. Receives: Behavioral: Minimal-Dose Home-Based Resistance Exercise |
| Standard of Care | No intervention | Subjects will be asked to follow standard of care recommendations as prescribed by the physician. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Performance fatigability
Performance fatigability will be assessed as change in maximal voluntary isometric contraction (MVIC) torque of the dominant leg. Change in MVIC torque from the initial MVIC contraction to the last MVIC contraction will be used to determine the Performance Fatigability index.
Measured: baseline and week 8
Secondary outcomes (15)
Rating of Perceived Fatigue (RPF)
Perceived fatigability will be assessed using a rating of perceived fatigue (RPF) scale.
0=no fatigue at all; 10=absolutely exhausted higher the value=more fatigue
Measured: baseline and week 8
Isometric and Isokinetic Knee Extensor Torque
Unilateral peak isometric and isokinetic knee extension torque (60º/s and 180º/s) will be obtained across five continuous repetitions using a dynamometer in a seated position per manufacturer guidelines (Biodex System 4).
Measured: baseline and week 8
Skeletal muscle oxygen extraction
Skeletal muscle oxygen extraction of the dominant vastus lateralis will be assessed non-invasively using near-infrared spectroscopy (NIRS) (Artinis, Portamon, The Netherlands).
Measured: baseline and week 8
Feeling Scale
Change's in affect during knee extensor performance fatigability testing will be assessed using the Feeling Scale. The Feeling Scale is an 11-point, single item, bipolar rating scale ranging from +5 to -5.
Measured: baseline and week 8
Fatigue Severity Scale (FSS)
9-item questionnaire assessing how fatigue interferes with certain activities and rates its severity according to a self-report scale. Items are scored on a 7-point scale with 1=strongly disagree and 7=strongly agree. higher the value=more impact fatigue has
Measured: baseline and week 8
Short Physical Performance Battery (SPPB)
SPPB will assess customary gait speed, side-by-side stand, semi-tandem stand, tandem stand, and 5-STS.
Measured: baseline and week 8
30-second sit-to-stand
subjects will be asked to perform as many sit-to-stand repetitions in 30 seconds.
Measured: baseline and week 8
Six Minute Walk Test (6MWT)
Subjects will be asked to walk as far as possible in 6 minutes.
Measured: baseline and week 8
Motor Unit Firing Rate
motor unit shape and firing behavior of the dominant leg vastus lateralis will be extracted using surface electromyographic signals (sEMG) and specialized software (Trigno NeuroMap System, Delsys Inc., Natick, MA, USA).
Measured: baseline and week 8
Muscle Activation
interpolated twitch technique will be applied to the femoral nerve using a constant-current, variable high-voltage stimulator (DS7R, Digitimer, Hertforshire, UK) to quantify muscle activation of the vastus lateralis.
Measured: baseline and week 8
peak VO2
Peak VO2 will be assessed from cardiopulmonary exercise testing using the Modified Bruce Protocol.
Measured: baseline and week 8
Health-related quality of life (SF-36)
The 36-item short-form (SF-36) is a multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.
Measured: baseline and week 8
Pittsburgh Fatigability Scale
26-item scale chosen from four activity categories; social, sedentary, lifestyle or light-intensity, and moderate-to-high-intensity.
Measured: baseline and week 8
Short-form Depression, Anxiety, and Stress Scale (DASS-21)
The DASS is designed to measure the negative emotional states of depression, anxiety, and stress.
Measured: baseline and week 8
Physical Activity Level
Physical activity levels will be monitored objectively using ActiGraph activity monitors
Measured: baseline and week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2023
- Study start31 Jul 2023
- Primary completion4 Jul 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled pilot study
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Jared M. Gollie, PhD, Principal investigator, Washington DC VA Medical Center, Washington, DC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05699538
- Sponsor's protocol ID
- F4371-P
- Status last verified
- May 2026
- First submitted
- 24 Jan 2023
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fatigue and Fatigability in Veterans Following SARS-CoV-2 Infection
- ClinicalTrials.gov ID
- NCT05699538
- Acronym / sponsor ID
- F4371-P
- Conditions
- Long COVID
- Keywords
- resistance exercise, fatigue, COVID-19, near infrared spectroscopy, strength
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 31 Jul 2023 (actual)
- Primary completion
- 4 Jul 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 26 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. The central hypothesis is that declines in force capacity, skeletal muscle oxygen extraction, and affective responses to physical activity offer potential mechanisms through which fatigability is increased in Veterans with post-COVID-19 fatigue. Moreover, home-based resistance exercise delivered remotely may provide a safe and feasibility treatment option for targeting neuromuscular and neurobehavioral factors influencing fatigability severity in this population.
Detailed description
The clinical case definition of post-COVID-19 condition (also referred to as Long COVID) as defined by the World Health Organization (WHO) includes individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Fatigue represents one of the most frequently reported symptoms in individuals experiencing post-COVID-19 (i.e., post-COVID-19 fatigue; PCF).Fatigue is shown to persist for months after SARS-CoV-2 infection, negatively impacting activities of daily living. For the purposes of this SPiRE proposal, fatigue is operationally defined as a state characteristic encompassing a subjective lack of physical and/or mental energy that is perceived by the individual to interfere with usual or desired activities.
Increased fatigability is a possible complication following SARS-CoV-2 infection due to the presence of both neuromuscular and neurobiological consequences. Skeletal muscle alterations including reduced force capacity, fiber atrophy, mitochondria and metabolic dysfunction, and capillary impairments have been observed in patients following SARS-CoV-2 infection. Autopsy reports of patients who died after SARS-CoV-2 infection found evidence of skeletal muscle atrophy of type 2 fibers, necrotizing myopathy, and myositis. Similarly, using nerve conduction studies, patients with long-term COVID-19 were found to have signs of myopathy, even those who were not hospitalized. Evidence from cardiopulmonary exercise testing in patients diagnosed with COVID-19 has revealed impaired skeletal muscle oxygen extraction, as opposed to central limitations (i.e., cardiac output), as a determinant of exercise intolerance. In addition to neuromuscular complications, SARS-CoV-2 infection has also been shown to be associated with psychiatric sequelae. Collectively, these findings underscore neuromuscular as well as neurobiological consequences of SARS-CoV-2 as potential independent or co-occurring mechanisms by which increased fatigability occurs and persists.
Despite widespread calls for the importance of rehabilitation in individuals recovering from SARS-CoV-2 infection, little progress has been made regarding the potential benefits of physical exercise on fatigue and fatigability in this population. Moreover, concerns have been raised about the applicability of physical exercise in patients recovering from SARS-CoV-2 infection. For example, while the health and functional benefits of exercise are vast and widely known, in certain patient populations exertion is shown to exacerbate symptom severity. Some individuals with PCF may report experiencing worsening of symptoms after physical or mental exertion. Home-based exercise may offer an appealing option for those individuals concerned about attending community fitness facilities. Home-based exercise is shown to produced moderate effects on muscle strength and balance. Presently, the exact dosing of home-based exercise to elicit positive outcomes in fatigability is unknown. Minimal-dose resistance exercise has been proposed as a potential strategy for improving neuromuscular characteristics and physical function. Minimal-dose resistance exercise uses little to no equipment with exercises performed at lower workloads. The investigators aim to adapt the "minimal-dose" resistance exercise paradigm to a remote home-based resistance exercise program for Veterans with PCF to determine its implications for reducing fatigability and improving neuromuscular and neurobiological factors. Minimal-dose resistance exercise for the proposed application is defined as a single, weekly body-weight exercise session.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized controlled pilot study
| Arm | Type | Receives |
|---|---|---|
| Minimal-Dose Home-Based Resistance Exercise | Experimental | Behavioral: Minimal-Dose Home-Based Resistance Exercise8-week home-based resistance exercise performed one day per week. |
| Standard of Care | No intervention | –Subjects will be asked to follow standard of care recommendations as prescribed by the physician. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- ambulatory patients (with or without a gait aid)
- 50 years of age or older
- with a confirmed diagnosis of COVID-19 by polymerase chain reaction (PCR) test, antibody test or clinical diagnosis
- the symptom of fatigue reported greater than 12-weeks post-infection (reporting fatigue: yes/no)
- receiving care at the DC VAMC
Key exclusion criteria (10 listed)
- <50 years of age without a confirmed diagnosis of COVID-19 by PCR test
- antibody test or clinical diagnosis or with a confirmed diagnosis of COVID-19 of <12-weeks
- non-ambulatory individuals
- Veterans who do not use the DC VAMC as their main site for care
- body mass index 40 kg/m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Minimal-Dose Home-Based Resistance Exercise8-week home-based resistance exercise performed one day per week. | Behavioural | Minimal-Dose Home-Based Resistance Exercise |
Primary outcome
Performance fatigability
Time frame: baseline and week 8
Performance fatigability will be assessed as change in maximal voluntary isometric contraction (MVIC) torque of the dominant leg. Change in MVIC torque from the initial MVIC contraction to the last MVIC contraction will be used to determine the Performance Fatigability index.
15 secondary outcomes
Rating of Perceived Fatigue (RPF)
Time frame: baseline and week 8
Isometric and Isokinetic Knee Extensor Torque
Time frame: baseline and week 8
Skeletal muscle oxygen extraction
Time frame: baseline and week 8
Feeling Scale
Time frame: baseline and week 8
Fatigue Severity Scale (FSS)
Time frame: baseline and week 8
Short Physical Performance Battery (SPPB)
Time frame: baseline and week 8
30-second sit-to-stand
Time frame: baseline and week 8
Six Minute Walk Test (6MWT)
Time frame: baseline and week 8
Motor Unit Firing Rate
Time frame: baseline and week 8
Muscle Activation
Time frame: baseline and week 8
peak VO2
Time frame: baseline and week 8
Health-related quality of life (SF-36)
Time frame: baseline and week 8
Pittsburgh Fatigability Scale
Time frame: baseline and week 8
Short-form Depression, Anxiety, and Stress Scale (DASS-21)
Time frame: baseline and week 8
Physical Activity Level
Time frame: baseline and week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Individual participant dataSharing planned: No
Related trials for Long COVID
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Enrolling by invitation
Fareon Open Label Device Clinical Trial
Cognitive Dysfunction, Acquired Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jared M. Gollie, PhD principal investigator
Washington DC VA Medical Center, Washington, DC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Minimal-Dose Home-Based Resistance Exercise in people with Long COVID, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Performance fatigability (time frame: baseline and week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.